ArticleFrontiers in cardiovascular medicine2026
Five-year cardiovascular outcomes across hypertensive disorders of pregnancy subtypes: a propensity-matched analysis.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertensive disorders of pregnancy (HDP) are established risk factors for future cardiovascular disease, yet long-term cardiovascular risk across specific HDP subtypes remains incompletely defined. Methods: We conducted a retrospective cohort study using a large, global electronic health record network to evaluate five-year cardiovascular outcomes among women with gestational hypertension, chronic hypertension, preeclampsia/eclampsia, and superimposed preeclampsia compared with normotensive pregnancies. Propensity score matching was performed to balance baseline demographic and cardiometabolic risk factors. Outcomes included heart failure, ischemic heart disease, stroke, pulmonary embolism, atrial fibrillation or flutter, and major adverse cardiovascular events (MACE). Results: After propensity score matching, 109,945 women with gestational hypertension, 36,560 with chronic hypertension, 94,198 with superimposed preeclampsia, and 80,848 with preeclampsia/eclampsia were each matched 1:1 with normotensive controls. Superimposed preeclampsia was associated with the largest observed odds of adverse cardiovascular outcomes, including heart failure (OR 3.80, 95% CI 3.46-4.16), stroke (OR 3.66, 95% CI 3.35-4.00), ischemic heart disease (OR 3.08, 95% CI 2.83-3.36), and MACE (OR 3.29, 95% CI 3.11-3.47). Chronic hypertension and preeclampsia/eclampsia demonstrated comparatively elevated risk, with chronic hypertension associated with increased odds of heart failure (OR 2.88, 95% CI 2.43-3.43) and MACE (OR 2.24, 95% CI 2.01-2.49), and preeclampsia/eclampsia associated with higher odds of heart failure (OR 3.10, 95% CI 2.62-3.65) and stroke (OR 2.29, 95% CI 1.99-2.63). Gestational hypertension was associated with increased odds of heart failure (OR 1.35, 95% CI 1.14-1.60) but not with most other cardiovascular outcomes. Conclusions: Long-term cardiovascular risk following HDP varies by subtype, with all major subtypes demonstrating increased risk compared with normotensive pregnancies and larger effect estimates observed among women with superimposed preeclampsia. These findings support consideration of hypertensive disorder subtype in postpartum cardiovascular risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.